A recent study published in the Journal of Cardiovascular Magnetic Resonance featured Myocardial Solutions’ technology MyoStrain, where MyoStrain was used to examine myocardial tissue function in Wilson Disease (WD) patients. WD, a storage disease that results in...
A new pivotal article validated Myocardial Solutions technology MyoStrain® (fSENC) for the early detection and prediction of cardiotoxicity (heart damage). The article was published in published in Circulation: Cardiovascular Imaging, Journal of the American Heart Association–one of the most ...
Most of the funds were raised from individuals and family offices. The Company’s post financing valuation is $93.2M. Among the business consequences of COVID...
Myocardial Solutions (“MSI”) technologies MyoStrain® (fSENC) was featured in a newly published article exploring the effectiveness of cardiovascular magnetic resonance (CMR) and segmental strain to detect ischemia in patients suspected of obstructive coronary artery disease (CAD)...
A new peer-reviewed study accepted in the Journal of the American College of Cardiology: Cardiovascular Imaging validated Myocardial Solutions (“MSI”) technologies MyoStrain and MyoStress in a new stress testing protocol utilizing a hyperventilation breath-hold (HVBH) maneuver to accurately ...
